IMMUNOVANT INC (IMVT) competitors & alternatives
Health Care · NASDAQ
IMMUNOVANT INC (IMVT)'s top competitors and alternatives — its most similar public companies — include Regeneron Pharmaceuticals (REGN), Amgen (AMGN), CLIMB BIO INC (CLYM), ELEDON PHARMACEUTICALS INC (ELDN), ZURA BIO LTD CLASS A (ZURA), BIOHAVEN LTD (BHVN), KYVERNA THERAPEUTICS INC (KYTX), ANNEXON INC (ANNX), NURIX THERAPEUTICS INC (NRIX), Aldeyra Therapeutics, Inc. (ALDX), EVOMMUNE INC (EVMN) and UPSTREAM BIO INC (UPB). These are IMMUNOVANT INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top IMVT competitors & alternatives
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
AmgenAMGNHealth Care
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone…
$366.05 (as of 2026-07-22) · market cap $197.7B
-
CLIMB BIO INCCLYMHealth Care
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and…
$12.58 (as of 2026-07-22) · market cap $720M
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
ZURA BIO LTD CLASS AZURAHealth Care
Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current…
$5.40 (as of 2026-07-22) · market cap $532M
-
BIOHAVEN LTDBHVNHealth Care
Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using…
$14.75 (as of 2026-07-22) · market cap $2.3B
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.40 (as of 2026-07-22) · market cap $452M
-
ANNEXON INCANNXHealth Care
Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical…
$5.23 (as of 2026-07-22) · market cap $857M
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
Aldeyra Therapeutics, Inc.ALDXHealth Care
Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on…
$1.70 (as of 2026-07-22) · market cap $106M
-
EVOMMUNE INCEVMNHealth Care
Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates…
$11.40 (as of 2026-07-22) · market cap $439M
-
UPSTREAM BIO INCUPBHealth Care
Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class monoclonal antibody targeting the TSLP receptor for the treatment of…
$6.59 (as of 2026-07-22) · market cap $376M
Not quite? Describe exactly what you want →
Peers are IMMUNOVANT INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: IMMUNOVANT INC (IMVT).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.